在神经退行症中准甲素:生物化学进步
Francesca Di Matteo1, Mariapia Vietri1, Simone D'Alessio1
1Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy.
Biomedicines
|December 30, 2025
概括
素是清除有毒蛋白质的关键蛋白酶,在神经退行性疾病中具有双重作用. 针对它们提供治疗潜力,但必须克服药物输送等挑战.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲素是溶解体蛋白质酶,通过清除错误折叠和聚合的蛋白质,对维持神经元蛋白质稳定至关重要.
- 甲素的失调与神经退行性疾病 (如阿尔茨海默病,帕金森病和亨廷顿病) 有关,这些疾病的特征是有毒蛋白质的积累.
研究的目的:
- 为了审查catepsins在与神经退行相关的细胞应激通路中的作用.
- 评估针对神经系统疾病的向甲素的治疗潜力.
主要方法:
- 关于甲素功能,抑制和调节的体外和体内研究的综合文献综述.
- 分析针对 cathepsins 的机制性见解和药理学策略.
- 评估将临床前发现转化为临床应用的挑战.
主要成果:
- 甲素表现出双重作用,通过聚合降解帮助神经元健康,但在失调时可能会使压力恶化.
- 甲素影响自,亡和神经炎症,在细胞内和细胞外都起作用.
- 临床转化受阻于抑制剂选择性差,脑透率有限和模型可变性.
结论:
- 向甲素是一种有前途的治疗策略,用于神经退行性和神经精神疾病.
- 仍然存在重大障碍,包括提高药物特异性和大脑输送.
- 未来的研究需要标准化的模型来提高对临床结果的预测.
关键词:
压力ERER压力ERER压力生物化学途径的发生.卡瑟普辛抑制剂的使用卡特赫普辛斯 (cathepsins) 的意思是说药物开发是药物的发展.线粒体功能障碍 线粒体功能障碍神经退行症的神经退行症神经退行性疾病是一种神经退行性疾病.更多相关视频
07:57An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
7.3K
10:45Monitoring Cleaved Caspase-3 Activity and Apoptosis of Immortalized Oligodendroglial Cells using Live-cell Imaging and Cleaveable Fluorogenic-dye Substrates Following Potassium-induced Membrane Depola
Published on: January 13, 2012
16.4K
相关概念视频
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
